Previous 10 | Next 10 |
Aeterna Zentaris (AEZS) jumps 6% in premarket, on amendment of its existing license agreement with Novo Nordisk (NVO) related to the development and commercialization of macimorelin.Under the amendment, Aeterna will continue to retain all rights to macimorelin outside of the U....
- Company to receive upfront payment of € 5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for childhood-on...
Aeterna Zentaris (AEZS): Q3 GAAP EPS of -$0.02.Revenue of $0.1M (-64.3% Y/Y)Press Release For further details see: Aeterna Zentaris reports Q3 results
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets – ...
Aeterna Zentaris ( AEZS -1.8% ) said it is preparing for Phase 3 (AEZS-130-P02) safety, efficacy study for its lead product macimorelin, and expects to commence the study in Q1 of 2021. The company is currently developing the product for the diagnosis of child-onset growth hormone d...
- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16 th at 11:00 AM EDT - CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercial...
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of macimorelin for validity testing in a Phase 3 trial, expected to commence in Q1 2021 - ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead The tech sector will be in focus again in the week ahead as investors gauge if short-term pandemic p...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Looking For Cheap Penny Stocks? How Do These Stack up? Penny stocks come in all shapes and sizes. Whether you’re simply looking for stocks under $5 or maybe you’re more specific to penny stocks under 10 cents, there’s something for everyone. In fact, there are even stock...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...